To include your compound in the COVID-19 Resource Center, submit it here.

Vivalis to merge with Intercell

Vivalis S.A. (Euronext:VLS) will merge with infectious disease company Intercell AG (VSE:ICLL; OTCQX:INRLY) in a stock deal that values Intercell at about EUR 132.5 million ($174.4 million). The

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE